Triapine
- Generic Name
- Triapine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H9N5S
- CAS Number
- 143621-35-6
- Unique Ingredient Identifier
- U4XIL4091C
- Background
Triapine has been used in trials studying the treatment of Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 1
Completed
- Conditions
- Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v6 and v7
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyDrug: Triapine
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00288093
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer
- Interventions
- Drug: triapineDrug: gemcitabine hydrochlorideOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 68
- Registration Number
- NCT00095888
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: triapineDrug: irinotecan hydrochlorideOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00084877
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
Phase 2
Completed
- Conditions
- Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 116
- Registration Number
- NCT00085371
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00081276
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: triapineDrug: doxorubicin hydrochlorideOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00079014
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 26
- Registration Number
- NCT00078975
- Locations
- 🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Recurrent Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00077350
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Phase 2
Completed
- Conditions
- Adenocarcinoma of the EsophagusRecurrent Esophageal CancerStage IV Esophageal Cancer
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00077545
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00077181
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath